胆汁的生成、分泌、排泄及胆汁淤积发生机制

申弘; 胡萌; 魏泽辉; 张冬; 张均倡; 田广俊

doi:10.3969/j.issn.1001-5256.2019.02.043

胆汁的生成、分泌、排泄及胆汁淤积发生机制

DOI: 10.3969/j.issn.1001-5256.2019.02.043

1. 广东省中医院珠海医院肝病科
2. 南方医科大学附属深圳医院中医科

基金项目:

国家自然科学基金(81273967)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1585
- HTML全文浏览量: 91
- PDF下载量: 1272
- 被引次数: 0
出版历程
- 收稿日期: 2018-11-07
- 出版日期: 2019-02-20

Bile formation, secretion, and excretion and the pathogenesis of cholestasis

Department of Hepatology, Zhuhai Branch of Guangdong Provincial Hospital of Traditional Chinese Medicine

Research funding:

摘要

摘要: 正常的胆汁生成、分泌、排泄是机体重要的生理过程。胆汁在促进脂质消化和吸收、清除机体代谢废物、调节胆固醇代谢等方面发挥着重要作用。当各种原因引起胆汁生成、分泌或排泄发生障碍时,则出现急性或慢性胆汁淤积性病变。深入了解胆汁生成、分泌、排泄及胆汁淤积的发生机制对于开展胆汁淤积性肝病相关研究和指导临床实践具有重要的意义。
- 胆汁淤积 /
- 胆汁酸类和盐类 /
- 综述
Abstract: Normal bile formation, secretion, and excretion are important physiological processes in human body. Bile plays an important role in promoting lipid digestion and absorption, eliminating metabolic waste, and regulating cholesterol metabolism. Disorders in bile formation, secretion, or excretion due to various causes may lead to acute or chronic cholestatic diseases. A deep understanding of the role of bile formation, secretion, and excretion and the pathogenesis of cholestasis is of great significance in the research on cholestatic liver diseases and clinical practice.
- cholestasis /
- bile acids and salts /
- review

HTML全文

参考文献(33)

[1]HUNDT M, JOHN S.Physiology, Bile Secretion[M].Stat Pearls Publishing, 2018.

[2]BOYER JL.Bile formation and secretion[J].Compr Physiol, 2013, 3 (3) :1035-1078.

[3]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.

[4]LI T, CHIANG JY.Bile acid signaling in metabolic disease and drug therapy[J].Pharmacol Rev, 2014, 66 (4) :948-983.

[5]SHAH R, JOHN S.Jaundice, Cholestatic (Cholestasis, Cholestatic Hepatitis) [M].Stat Pearls Publishing, 2018.

[6]POLLOCK G, MINUK GY.Diagnostic considerations for cholestatic liver disease[J].J Gastroenterol Hepatol, 2017, 32 (7) :1303-1309.

[7]SLIJEPCEVIC D, van de GRAAF SF.Bile acid uptake transporters as targets for therapy[J].Dig Dis, 2017, 35 (3) :251-258.

[8]SLIJEPCEVIC D, ROSCAM ABBING RLP, KATAFUCHI T, et al.Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice[J].Hepatology, 2017, 66 (5) :1631-1643.

[9]STICOVA E, JIRSA M, PAWOWSKA J.New insights in genetic cholestasis:From molecular mechanisms to clinical implications[J].Can J Gastroenterol Hepatol, 2018, 2018:2313675.

[10]LI T, APTE U.Bile acid metabolism and signaling in cholestasis, inflammation, and cancer[J].Adv Pharmacol, 2015, 74:263-302.

[11]VAZ FM, PAULUSMA CC, HUIDEKOPER H, et al.Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency:Conjugated hypercholanemia without a clear clinical phenotype[J].Hepatology, 2015, 61 (1) :260-267.

[12]HAGENBUCH B, STIEGER B.The SLCO (former SLC21) superfamily of transporters[J].Mol Aspects Med, 2013, 34 (2-3) :396-412.

[13]TTH B, JANI M, BERY E, et al.Human OATP1B1 (SLCO1B1) transports sulfated bile acids and bile salts with particular efficiency[J].Toxicol In Vitro, 2018, 52:189-194.

[14]THOMSON MM, HINES RN, SCHUETZ EG, et al.Expression patterns of organic anion transporting polypeptides 1B1 and1B3 protein in human pediatric liver[J].Drug Metab Dispos, 2016, 44 (7) :999-1004.

[15]THAKKAR N, SLIZGI JR, BROUWER KLR.Effect of liver disease on hepatic transporter expression and function[J].JPharm Sci, 2017, 106 (9) :2282-2294.

[16]NIGAM SK, BUSH KT, MARTOVETSKY G, et al.The organic anion transporter (OAT) family:A systems biology perspective[J].Physiol Rev, 2015, 95 (1) :83-123.

[17]SLOPIANKA M, HERRMANN A, PAVKOVIC M, et al.Quantitative targeted bile acid profiling as new markers for DILI in a model of methapyrilene-induced liver injury in rats[J].Toxicology, 2017, 386 (7) :1-10.

[18]WAGNER DJ, HU T, WANG J.Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics[J].Pharmacol Res, 2016, 111:237-246.

[19]ZOLLNER G, WAGNER M, FICKERT P, et al.Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis[J].Liver Int, 2007, 27 (7) :920-929.

[20]MEMON N, WEINBERGER BI, HEGYI T, et al.Inherited disorders of bilirubin clearance[J].Pediatr Res, 2016, 79 (3) :378-386.

[21]SOROKA CJ, BOYER JL.Biosynthesis and trafficking of the bile salt export pump, BSEP:Therapeutic implications of BSEP mutations[J].Mol Aspects Med, 2014, 37 (2) :3-14.

[22]RIEDE J, POLLER B, HUWYLER J, et al.Assessing the risk of drug-induced cholestasis using unbound intrahepatic concentrations[J].Drug Metab Dispos, 2017, 45 (5) :523-531.

[23]YU XH, QIAN K, JIANG N, et al.ABCG5/ABCG8 in cholesterol excretion and atherosclerosis[J].Clin Chim Acta, 2014, 428 (2) :82-88.

[24]FERRIGNO A, DI PASQUA LG, BERARDO C, et al.The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury[J].PLo S One, 2018, 13 (1) :e0191430.

[25]TARDELLI M, CLAUDEL T, BRUSCHI FV, et al.Nuclear receptor regulation of aquaglyceroporins in metabolic organs[J].Int J Mol Sci, 2018, 19 (6) :e1777.

[26]PENG H, ZHU QS, ZHONG S, et al.Transcription of the human microsomal epoxide hydrolase gene (EPHX1) is regulated by PARP-1 and histone H1.2.association with sodiumdependent bile acid transport[J].PLo S One, 2015, 10 (5) :e0125318.

[27]KEPPLER D.Cholestasis and the role of basolateral efflux pumps[J].Z Gastroenterol, 2011, 49 (12) :1553-1557.

[28]HALILBASIC E, CLAUDEL T, TRAUNER M.Bile acid transporters and regulatory nuclear receptors in the liver and beyond[J].J Hepatol, 2013, 58 (1) :155-168.

[29]CHEUNG AC, LORENZO PISARELLO MJ, LARUSSO NF.Pathobiology of biliary epithelia[J].Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt B) :1220-1231.

[30]LI XF, GONG JY, WANG JS.Association between enterohepatic circulation of bile acid and cholestatic liver disease[J].JClin Hepatol, 2017, 33 (10) :1922-1927. (in Chinese) 李晓峰, 龚敬宇, 王建设.胆汁酸的肠肝循环与胆汁淤积性肝病[J].临床肝胆病杂志, 2017, 33 (10) :1922-1927.

[31]BAGHDASARYAN A, FUCHS CD, STERREICHER CH, et al.Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis[J].J Hepatol, 2016, 64 (3) :674-681.

[32]HAMOUD AR, WEAVER L, STEC DE, et al.Bilirubin in the livergut signaling axis[J].Trends Endocrinol Metab, 2018, 29 (3) :140-150.

[33]LU LG.Hotspots and difficulties of clinical and basic research in cholestatic liver disease[J].Chin J Hepatol, 2015, 23 (8) :561-563. (in Chinese) 陆伦根.胆汁淤积性肝病临床和基础研究热点和难点[J].中华肝脏病杂志, 2015, 23 (8) :561-563.

施引文献

资源附件(0)

访问统计